Location History:
- Guangdong, CN (2014)
- Guangzhou, CN (2010 - 2021)
Company Filing History:
2 out of 12 
2 out of 1,039 
Years Active: 2010-2021
Title: Erwei Song: Innovator in Cancer Therapeutics
Introduction
Erwei Song is a prominent inventor based in Guangzhou, China, known for his significant contributions to cancer therapeutics. With a total of four patents to his name, he has focused on innovative methods to treat and prevent cancer, particularly by targeting cancer stem cells.
Latest Patents
One of Erwei Song's latest patents is titled "Let-7 microRNA and mimetics thereof as therapeutics for cancer." This invention relates to methods for treating or preventing cancers by targeting cancer stem cells through the administration of specific microRNAs. The patent emphasizes the importance of let-7 miRNAs, which are often reduced or absent in cancer stem cells. Additionally, the invention outlines methods to enrich cancer stem cell populations and identify miRNAs that contribute to their self-renewal capacity. Another notable patent is "Method of delivering RNA interference and uses thereof," which describes a method of RNA interference involving a fusion protein-double stranded RNA complex. This complex is designed to initiate RNA interference in target cells, showcasing innovative approaches to gene regulation.
Career Highlights
Throughout his career, Erwei Song has worked with esteemed organizations such as the Immune Disease Institute, Inc. and the Children's Medical Center Corporation. His work in these institutions has allowed him to advance his research and contribute to the field of cancer therapeutics.
Collaborations
Erwei Song has collaborated with notable professionals in his field, including Judy Lieberman and Manjunath Narasimhaswamy. These collaborations have further enriched his research and innovation efforts.
Conclusion
Erwei Song's work in cancer therapeutics exemplifies the impact of innovative thinking in medicine. His patents reflect a commitment to advancing treatment options for cancer patients, particularly through the targeting of cancer stem cells. His contributions are significant in the ongoing fight against cancer.